Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)-Reference-Cited by-同舟云学术

Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)

Published:2022-03-08 Issue:6 Volume:135 Page:697-706
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Xin Ling,Wu Qian,Zhan Chongming,Qin Hongyan,Xiang Hongyu,Xu Ling,Ye Jingming,Duan Xuening,Liu Yinhua

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference17 articles.

1. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis;Broglio;JAMA Oncol,2016

2. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis;Spring;Clin Cancer Res,2020

3. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study;Modi;J Clin Oncol,2020

4. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update;Wolff;J Clin Oncol,2013

5. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer;Hammond;J Oncol Pract,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification;Cancer Cell International;2024-03-30

2. Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China;Targeted Oncology;2024-01

3. Improving HER2-Positive Breast Cancer Targeted Therapy Prediction Using multiMSnet: A Multi-Scale Pathological Image-Based Approach;2023 IEEE International Conference on Data Mining Workshops (ICDMW);2023-12-04

4. A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression;Chinese Medical Journal;2023-10-11

5. Evolution of Breast Cancer Recurrence Risk Prediction: A Systematic Review of Statistical and Machine Learning–Based Models;JCO Clinical Cancer Informatics;2023-08